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ocal segmental glomerulosclerosis (FSGS) is one of
the most common causes of nephrotic syndrome in
adults, and the incidence of this diagnosis is
increasing.1–4 This histological diagnosis can result
from many conditions such as reﬂux nephropathy,
signiﬁcant obesity, or genetic mutations affecting
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structural elements of the glomerular ﬁltration barrier.
The idiopathic form of this disease is due to a circulating factor(s) that disrupt the glomerular ﬁltration
barrier, resulting in widespread podocyte foot process
effacement (FPE) and proteinuria.5–7 Reported recurrence rates following the ﬁrst kidney transplantation
Kidney International Reports (2020) 5, 1510–1531
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vary between 10% and 86%.8,9,S1 Following a repeat
transplantation, after an initial recurrence, the recurrence rate is approximately 90%.S1,S2 Recurrence posttransplantation can result in signiﬁcantly premature
graft loss.9,S2 The circulating factor(s) responsible for
idiopathic FSGS remain elusive.
Many investigators have proposed various clinical
and or histological markers, or a combination thereof,
to identify primary idiopathic FSGS.9,S1,S3–S5 None of
these have been able to predict recurrence following
kidney transplantation with accuracy greater than
86%. Currently, the diagnosis of recurrent primary
FSGS is made clinically, that is, development of proteinuria early after transplantation.5,S1,S2 However, in a
number of patients, proteinuria develops later. The
true speciﬁcity of disease recurrence following transplantation has not been examined.
We present 3 transplant recipients who developed
early post-transplantation FSGS following transplantation (1 patient for the third time) who were
found to have etiologies other than idiopathic FSGS.
Being aware of these etiologies may prevent unnecessary therapy and also allow for better cohort deﬁnition, enabling identiﬁcation of the elusive circulating
factor(s).
CASE 1
A 23-year-old African American man was found to
have hypertension, nephrotic range proteinuria, and
advanced renal failure. His kidneys were small and
atrophic bilaterally, precluding native kidney biopsy.
There was no history of nephrotoxic agents or family
history of kidney disease.

After 5 years on dialysis, he received a deceased
donor kidney transplant from an 18-year-old African
American donor. Implantation biopsy was without
any abnormality. Immunosuppression was induced
with alemtuzumab and maintained with dual therapy
consisting of tacrolimus and mycophenolate mofetil.
Because of concerns that he had primary FSGS, he
was placed on a heightened post-transplantation
monitoring regimen for albuminuria. The initial
post-transplantation course was uneventful, with a
normal protocol allograft biopsy at 4 months posttransplantation and normal urine albumin excretion.
At 6 months post-transplantation, increasing albumin
excretion peaking at 3.4 g/g creatinine with stable
serum creatinine was noted (Figure 1). Allograft biopsy showed segmental sclerosis in 2 of 15 glomeruli,
both of which had associated overlying podocyte
reaction and protein resorption granules, with patchy
mild mononuclear cell inﬁltrates involving less than
10% of the cortex with associated focal mild tubulitis. This was initially interpreted as clinically
recurrent FSGS with borderline changes for rejection
(Figure 2). Electron microscopy, however, showed
largely intact podocyte foot processes.
Treatment for the borderline rejection consisted of 5
consecutive days of parenteral methylprednisolone
with decreasing dosage, followed by a rapid oral
prednisone taper to 5 mg over 7 days. Given the lack of
podocyte FPE, no speciﬁc therapy for recurrent FSGS
was undertaken. Losartan 25 mg daily was substituted
for amlodipine 5 mg daily for blood pressure control.
A postrejection therapy follow-up biopsy sample
was obtained 4 weeks later and was normal.

Figure 1. Trends of serum creatinine, random albumin/creatinine ratio, 24-hour albumin excretion, and serum albumin from case 1. Steroid
therapy for borderline acute cellular rejection.
Kidney International Reports (2020) 5, 1510–1531
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Figure 2. Pathology of the 7-month post-transplantation kidney allograft biopsy from case 1: (a) light microscopy (original magniﬁcation 40,
periodic acid–Schiff) and (b) light microscopy (original magniﬁcation 40, Jones), both showing segmental sclerosis in glomeruli with overlying
podocyte reaction; and (c) electron microscopy photomicrograph demonstrating intact podocyte foot processes.

Albuminuria decreased gradually over the following 4
months to <1 g/g creatinine, then to <0.5 g/g creatinine over the subsequent 2 months and has remained in
the range of 0.3 to 0.4 g/g creatinine over 2 years of
follow-up (Figure 1). Blood pressure and renal function
were stable throughout.
Given the unusual presentation, a thorough workup
for secondary causes of FSGS was undertaken. This
included apolipoprotein L 1 (APOL-1) testing of the
recipient and donor. The recipient was homozygous for
the average risk alleles, and the donor was homozygous
for the high-risk allele G1.
Interestingly, we were contacted by the center that
transplanted the mate kidney of this recipient (see Case 2).
CASE 2
A 70-year-old Caucasian woman who developed endstage renal disease (ESRD) attributed to hypertensive
diabetic nephrosclerosis received a deceased donor
kidney transplant after 2.5 years of dialysis. Her
calculated panel reactive antibodies (cPRA) were 100%.
Prior to transplantation, she underwent desensitization
using plasma exchange (PLEX) and i.v. Ig. B-cell ﬂow
crossmatch was weakly positive at the time of transplantation. Induction was with antithymocyte globulin, and the patient was maintained on triple
immunosuppressive therapy consisting of corticosteroids, mycophenolate mofetil, and tacrolimus. Post1520

transplantation she received rituximab and i.v. Ig
and required a blood transfusion. One week
post-transplantation there was an increase in donorspeciﬁc antihuman leukocyte antigen (HLA)
antibodies (DSA). PLEX, i.v. Ig, and bortezomib were
administered, followed by a decrease in DSA levels.
Creatinine remained at baseline of 0.9 to 1.1 mg/dl. One
year post-transplantation proteinuria was noted at 4.3
g/g creatinine. Previous levels were <0.35 g/g creatinine, with the most proximate level being 40 weeks
before the detection of the nephrotic range proteinuria.
Renal allograft biopsy showed de novo collapsing glomerulopathy with extensive FPE. Testing for HIV,
Epstein-Barr virus, and Parvo virus was negative by
polymerase chain reaction. The patient was started on
an angiotensin receptor blocker. Her proteinuria
increased to 10 g/g creatinine, at which point she underwent 5 sessions of PLEX and received additional
rituximab and i.v. Ig. There was a transient decrease in
proteinuria to 4.9 with stable graft function. Two
months, later proteinuria increased to 11 g/g creatinine.
Four months afterward, graft function began to deteriorate, with an increase in the baseline creatinine to
1.5 to 1.9 mg/dl, and 8 months later it was 4 mg/dl. A
second allograft biopsy sample showed advanced focal
and segmental sclerosis with no evidence of rejection
but some ﬁndings suggestive of allograft pyelonephritis. An Escherichia coli urinary tract infection at that
time was treated, with no improvement in renal
Kidney International Reports (2020) 5, 1510–1531
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Figure 3. Trends of serum creatinine, random albumin/creatinine ratio, 24-hour albumin excretion, and serum albumin from case 3. IVC, inferior
vena cava.

function. Creatinine remained at 4.1 mg/dl and proteinuria consistently >20 g/g creatinine. The patient
returned to maintenance hemodialysis 30 months posttransplantation.
CASE 3
A 40-year-old Caucasian man with ESRD from biopsyproven FSGS at age 16 years received his third living
donor kidney transplant. His 2 prior renal allografts
had been diagnosed with recurrent FSGS, but their
failures were slowly progressive.
The ﬁrst transplant was a living donor transplant
from his mother. Early complications included 2
biopsy-proven acute cellular rejection episodes that
were successfully treated, and 2 thrombotic events.
These consisted of renal vein thrombosis, requiring
thrombectomy, and lower extremity deep vein thrombosis. Because of these 2 events, lifelong anticoagulation was commenced. Eight months after the
ﬁrst kidney transplantation, the patient had increasing
serum creatinine and proteinuria. A biopsy sample
showed FPE and swollen visceral epithelial cells. Proteinuria progressed, and at 2 years post-transplantation
the biopsy sample showed established FSGS lesions
with diffuse FPE. Graft function continued to decline
slowly, with ongoing heavy proteinuria. At 10 years
post-transplantation a biopsy sample continued to
show similar features but with worsening interstitial
ﬁbrosis and tubular atrophy. In preparation for a second transplant, imaging revealed an allograft renal cell
carcinoma, and the patient underwent an allograft
Kidney International Reports (2020) 5, 1510–1531

nephrectomy 1 month prior to receiving his second
living donor transplant. At the time of the second
transplantation, the inferior vena cava (IVC) was noted
to be occluded by thrombus but with good collateral
drainage. The second transplant functioned well
initially. The protocol 3-month post-transplantation
allograft biopsy revealed moderate segmental podocyte FPE that was interpreted as early recurrent FSGS
with low-level albuminuria (213617 mg/g). Conservative therapy was undertaken. At 1 year, the albuminuria increased to 1386 mg/g and the protocol
biopsy showed 60% FPE. By 2 years, albuminuria
progressed to 3494 mg/g and the protocol biopsy
revealed 70% to 80% FPE with 1 of 12 glomeruli
exhibiting a segmental scar with foam cells and an
adhesion to the Bowman capsule. Based on these ﬁndings, a course of PLEX was undertaken, but there was
no signiﬁcant response. Rituximab was considered but
not administered, given the lack of response to the
PLEX. Albuminuria ﬂuctuated between 2 and 4 g/g
creatinine over the remainder of the life of the allograft.
Eight years after this second transplantation, the patient underwent an allograft nephrectomy with simultaneous living donor transplant. This combined
procedure was undertaken because of the ﬁnding on
computed tomographic venography that the iliac veins
and IVC were occluded and that the venous pedicle of
the second allograft was the only feasible location to
attach the third kidney allograft.
For this third transplant, the patient underwent our
center’s current standard conditioning for high-risk
FSGS recipients. This consisted of 2 doses of
1521
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Figure 4. Pathology of renal allograft biopsy samples from case 3. (a) Electron microscopy photomicrograph showing diffuse podocyte foot
process effacement and (b) light microscopy (original magniﬁcation 40, periodic acid–Schiff) demonstrating segmental sclerosis with hyalinosis (both from the second renal allograft). (c) Electron microscopy photomicrograph demonstrating minimal podocyte foot process
effacement and (d) LM (original magniﬁcation 20, periodic acid–Schiff) showing normal glomeruli (both from the third renal allograft).

rituximab (1 g each) and 4 sessions of PLEX prior to
transplantation and careful follow-up of posttransplantation albuminuria. The donor was a 68year-old man with treated hypertension.
The patient’s post-transplantation course was
complicated by slow graft function and ﬂuctuating
proteinuria punctuated by repeated episodes of acute
kidney injury (Figure 3). On post-transplantation day
3, because of increasing albuminuria, PLEX was initiated. A day 4 renal allograft biopsy showed acute
tubular injury and focal (20%30%) FPE. With subsequent decline in albuminuria, PLEX was discontinued on day 5.
Graft function and albuminuria continued to ﬂuctuate, and a biopsy sample 50 days after transplantation
showed negligible FPE. At this time, because of the age
of the donor and the donor-derived chronic vascular
changes noted in the allograft, belatacept was
substituted for tacrolimus. Despite this, there was still
ongoing suboptimal renal function and ﬂuctuating
albuminuria. Four months post-transplantation, biopsy
showed focal FPE with proteinuria of 2890 mg/24 h
(Figure 4).
1522

At this 4-month visit, given the past medical history
of veno-occlusive disease and the atypical posttransplantation course, other potential causes of suboptimal graft function and proteinuria were investigated. Despite a normal renal allograft ultrasound and
Doppler not revealing renal vein thrombosis or
abnormal resistive indices, we proceeded with an
inferior venacavogram. A successful balloon venoplasty of the occluded vena cava was accomplished
(Figure 5). The pressure gradient from the external iliac
vein to the right atrium decreased from 11 to 12 mm Hg
to 5 to 6 mmHg. Following this, renal allograft function
improved dramatically, with normalization of urine
albumin excretion. Two months later, to avoid possible
restenosis, a repeat cavogram was performed with
stenting of the inferior vena cava (Figure 5).
At the 2-year protocol visit, the patient continued to
have normal urine albumin excretion. The protocol 2year post-transplantation biopsy sample showed
intact podocyte foot processes.
The collection of data and presentation of these cases
and this study was approved by the Mayo Clinic
Institutional Review Board (IRB# 18-007788) and are
Kidney International Reports (2020) 5, 1510–1531
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Figure 5. Photographs from the cavogram of case 3 (a) occluded inferior vena cava (IVC) with guidewire traversing the obstruction, (b) after IVC
dilation, and (c) after IVC stenting.

consistent with the Principles of the Declaration of
Istanbul as outlined in the Declaration of Istanbul on
Organ Trafﬁcking and Transplant Tourism.
DISCUSSION
These cases illustrate the difﬁculty, and possible pitfalls, in making a diagnosis of recurrent FSGS. In the
ﬁrst case, the pretransplantation probability of FSGS
was moderate. There was no native biopsy sample and
no clear history of nephrotic syndrome. The increasing
proteinuria and the light microscopic ﬁndings of 2 of
15 glomeruli with segmental lesions, and reactive
podocytes made the diagnosis of recurrent primary
idiopathic FSGS likely. This constellation of ﬁndings,
in many centers including our own, would have
resulted in initiation of PLEX with or without highdose corticosteroids to treat what would be bona ﬁde
FSGS, be it recurrent or de novo. The rapid turnaround
of electron microscopy (EM) results that showed intact
podocyte foot processes allowed a pause and rethinking
of what this clinical scenario represented. Early
recurrent FSGS presents with diffuse FPE, generally
with normal glomerular histology on light microscopy.S6,S7 This case had the opposite ﬁndings: namely,
FSGS lesions noted on LM, but intact foot processes on
EM in the setting of new-onset and worsening proteinuria. The response to a short course of corticosteroids to treat the borderline cellular rejection was also
unlikely to have resulted in resolution of recurrent or
de novo FSGS.
So why did this patient develop this increasing
albuminuria? Why did it resolve with a short course of
Kidney International Reports (2020) 5, 1510–1531

corticosteroids? We postulate that the patient was doing well until his 4-month visit, which included a
reassuring protocol biopsy. Subsequent to this, there
could have been a transient decrease in tacrolimus
levels resulting in the borderline cellular rejection that
was noted on the biopsy sample. The activation of the
immune system targeting the renal allograft with allograft inﬂammation would have resulted in increased
inﬂammatory cytokines, including interferon-g and
tumor necrosis factor–a.S8 Tumor necrosis factor–a–
related pathways have been implicated in FSGS previously.S9–S12 With the homozygosity of the high-risk
APOL-1 alleles, the podocytes would have been susceptible to this inﬂammatory milieu,S13–S15 and some of
them succumbed, resulting in the increased proteinuria
and the segmental lesions that were seen on the biopsy
sample. The cell-mediated injury may not have been
diffuse in our case, given the patchy nature of cellular
rejection and as such may not have resulted in widespread diffuse FPE. It may also have been very transient or improving prior to the biopsy, possibly due to
increased levels of the immunosuppressants, and was
not picked up at the time of the biopsy. In the mate
kidney that was placed in a highly sensitized patient
with increasing DSA, the more diffuse pattern of injury
commensurate with the humoral response may have
resulted in widespread podocyte dysfunction resulting
in the collapsing FSGS. A similar presentation was
previously reported in a transplant recipient.S16
APOL-1 has surfaced as a genetic variant that
partially explains the increased risk of hypertensive
ESRD associated with FSGS in the African American
population, as well as in other populations in West
1523
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Africa or with West African heritage.S15,S17–S19 Patients
who are homozygous for 2 high-risk alleles either G1 or
G2 or a combination of both are at increased risk for
ESRD from FSGS and hypertension (odds ratio ¼ 10.5,
95% conﬁdence interval ¼ 6.018.4, and odds ratio ¼
7.3, 95% conﬁdence interval ¼ 5.69.5, respectively).S17 These patients are also at increased risk for
HIV-associated nephropathy (HIVAN) with a lifetime
risk of ESRD of 50% versus 4%, respectively.S19,S20
APOL-1 is expressed in many tissues and is present in
the circulation.S21 That the constitutive APOL-1 in the
kidney is responsible for increased risk of dysfunction
was alluded to by the ﬁnding that kidneys from donors
who expressed 2 high-risk alleles had shorter graft
survival irrespective of the recipients’ APOL-1 status.S14,S22 Our patient was homozygous for the average
risk (wild-type or reference) allele and the donor kidney
was homozygous for the high-risk allele (G 1), providing
further evidence that the intrinsic APOL-1, independent
of the circulating form, confers risk.S23,S24
In the third case, the converse regarding the preand post-transplantation probability of FSGS was present. The pretransplantation probability of recurrent
FSGS was very high, given a native kidney disease that
was diagnosed clinically and histologically and 2 prior
renal allografts with clinical and histological ﬁndings of
FSGS; hence the pretreatment with PLEX and rituximab. The post-transplantation ﬁndings on biopsy were
less typical of what we frequently see. The FPE was
focal and not diffuse, the proteinuria ﬂuctuated, and
renal function was erratic and suboptimal. One plausible explanation that could be proposed for the lack of
diffuse FPE in this and similar situations is that this
was partially treated FSGS by the pretransplantation
PLEX and rituximab, post-transplantation PLEX, and
the standard triple immunosuppression therapy needed
for an allograft. The suboptimal renal allograft function
could also be attributed to an older and hypertensive
donor kidney showing minor vascular changes and
resulting in oversensitivity to tacrolimus. Noted,
however, was the lack of improvement with the transition to belatacept and discontinuation of the calcineurin inhibitor tacrolimus.S25–S27
The signiﬁcant improvement in renal function and
albuminuria following venoplasty and subsequent
stenting of the inferior vena cava, with documented
improvement in the venous pressure gradient, is evidence that the dysfunction was due to venous hypertension. It is known that renal vein thrombosis
manifests with heavy proteinuria,S28 the mechanism
being an elevation in intraglomerular pressure and increase in transcapillary ﬁltration pressure gradient.
Partial occlusion or other causes of elevated venous
1524

pressures such as right-sided heart failure can also lead
to similar ﬁndings.S29
Could this patient’s prior 2 allografts have been
affected by a similar phenomenon? In contrast to the
current allograft, the prior renal allografts had good
renal function for extended periods of time. Also, the
progression of proteinuria and the diffuse podocyte
FPE was more in keeping with recurrent FSGS. Could
this patient develop recurrent late FSGS? Time will tell.
This case does highlight the difﬁculty in investigating
venous hypertension as the cause of renal allograft
dysfunction. There is no reliable noninvasive means of
assessing renal vein pressures. We rely on renal allograft ultrasound with Doppler to assess venous ﬂow
and to exclude occlusion. Echocardiography can assess
right-sided heart pressures and in turn may reﬂect
elevated venous pressures, although only if a more
central origin is the cause. The only reliable means of
measuring renal vein pressure is via venography.
Venography is invasive and carries risks of the procedure as well as contrast exposure. Thus, there is
considerable hesitation in proceeding with such invasive testing.
We demonstrated that even in the setting of biopsy
ﬁndings of FSGS and a post-transplantation state with
careful follow-up, there is difﬁculty in identifying
recurrent FSGS due to a circulating permeability factor. An incorrect labeling of a case has implications
for the individual patient being treated and for
studies attempting to identify the circulating permeability factor. For the patient, this may result in unnecessary therapy with associated comorbidity, cost,
and possible failure to identify a treatable condition.
For investigators, this will result in study groupings
that include heterogeneous cases, increasing the likelihood of identifying markers that are in common
pathways for proteinuric renal disease or podocyte
injury, and may not identify the circulating permeability factor(s).
In conclusion, donor derived APOL-1 high-risk alleles intrinsic to the renal allograft, and not the recipient, confer risk of proteinuria and development of
FSGS lesion in the kidney. These allografts may be
susceptible to the injurious effects of both the cellular
and humoral arms of the immune system. Venous hypertension can mimic recurrent FSGS and, in the correct circumstance, warrants invasive testing. Scrutiny
of FSGS cohorts is imperative in the quest to identify
the circulating permeability factor(s).
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etformin is widely used as an antihyperglycemic
drug to treat patients with type 2 diabetes.
Because metformin is renally excreted and not metabolized, it can accumulate in patients with renal
insufﬁciency and cause lactic acidosis, known as
metformin-associated lactic acidosis (MALA).1,2 The reported incidence of MALA ranges from 3 to 10 per
100,000 patient-years and is associated with a high
mortality rate. However, the full clinical context or
metformin blood concentration is often not reported,
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making it challenging to distinguish metforminassociated from metformin-induced lactic acidosis
(MILA), respectively.1
Normally, metformin shows 2-compartment pharmacokinetics with a terminal half-life of 20 hours,
suggesting the existence of a deeper compartment.2
After oral administration to mice, accumulation of
metformin was observed in the gut, kidneys, and
liver.3 After 6 to 8 weeks of metformin therapy given
to drug-naive patients with type 2 diabetes, the
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